We continue to boost manufacturing capacity in pharma sector: Govt

The total outlay of the Production Linked Incentive (PLI) scheme is Rs. 15,000 crore and financial incentives is provided to the selected participants on incremental sales for a period of six years

0
29
New Delhi: “With a view to attain self-reliance and reduce import dependence in critical Active Pharma Ingredients (APIs), a scheme called Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) and Drug Intermediates (DIs) in India was approved by the government recently. The total outlay of the scheme is Rs.6,940 crore and financial incentive under the scheme is provided to the selected participants on incremental sales of 41 identified products in four different target segments for a period of six years,” stated the Union Minister of Chemicals and Fertilizers, Dr. Mansukh Mandaviya in the upper house of the parliament.
The Minister added further: “Another Scheme called “Production Linked Incentive Scheme for Pharmaceuticals” was approved by the Government of India in March, 2021 to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector. The total outlay of the scheme is Rs. 15,000 crore and financial incentives is provided to the selected participants on incremental sales for a period of six years.”
“Under the PLI Scheme for Bulk Drugs, 50 applicants have been approved. Whereas under the PLI Scheme for Pharmaceuticals, 55 applicants have been approved. The details of approved applicants under both the Schemes are available at the website of the Department, viz., pharmaceuticals.gov.in,” Mandaviya informed.